Tests an automated insulin pump in pregnant people with type 2 diabetes
Tests an automated insulin pump and glucose sensor in pregnant adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Type 2 Diabetes and Pregnancy a Single-arm Interventional Study
Key facts
- Where
- Poznan, PolandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT07602036, who can take part
Where in Poland
- Heliodor Swiecicki Clinical Gynecology and Obstetrics Hospital of Poznan University of Medical SciencesPoznan, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Poznan University of Medical Sciences
- Trial code
- NCT07602036
- Record updated
- 10 November 2026
- Original description
This single-arm interventional study evaluates the MiniMed 780G insulin pump and continuous glucose monitoring (CGM) system in pregnant women with type 2 diabetes enrolled at ≤ 16 weeks gestation. From recruitment to delivery, participants attend regular clinical visits for active insulin adjustments. The primary objective is to measure the percentage of time spent in the target pregnancy glucose range (63-140 mg/dL). Secondary outcomes track mean glucose, HbA1c, and overall maternal and neonatal health to ensure safety and efficacy.Read full original descriptionShow less
Type 2 Diabetes and Pregnancy a Single-arm Interventional Study
This single-arm interventional study evaluates the MiniMed 780G insulin pump and continuous glucose monitoring (CGM) system in pregnant women with type 2 diabetes enrolled at ≤ 16 weeks gestation. From recruitment to delivery, participants attend regular clinical visits for active insulin adjustments. The primary objective is to measure the percentage of time spent in the target pregnancy glucose range (63-140 mg/dL). Secondary outcomes track mean glucose, HbA1c, and overall maternal and neonatal health to ensure safety and efficacy.
Inclusion: Women with diagnosed pregestational type 2 diabetes or HbA1c >6.5% in the 1st trimester (ADA, PTD); Age 18-45 years; Gestational age of 16 weeks +0 days or less at baseline; Singleton pregnancy; HbA1c at baseline 5.0-10%; A viable pregnancy at the recruitment; Willingness to continue the treatment until delivery in the clinic.
Exclusion: Pump therapy before pregnancy; Other types of diabetes including T1D and Monogenic diabetes; Severe nephropathy, psychiatric illness or other serious medical disorder that in the judgment of the investigator could affect completion of the trial; Major fetal congenital defects.